Gilead Sciences, Inc.
Gilead Sciences, Inc.
Your view on GILD
Overview
What the company does, where it operates, and who runs it.
About Gilead Sciences, Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Daniel P. O'Day
- Headquarters
- 333 Lakeside Drive, Foster City, CA, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Daniel P. O'Day
- Headquarters
- 333 Lakeside Drive, Foster City, CA, US
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.
; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Gilead Sciences, Inc. from FRC's valuation model, read against the market price. GILD last traded at $167.58; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Gilead Sciences, Inc.. Starting points for Gilead Sciences, Inc.: EPS -$3.11, beta 0.36 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Gilead Sciences, Inc.. Gilead Sciences, Inc. paid $3.25 per share over the last year — a 1.9% yield at the current $167.58 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Gilead Sciences, Inc.. Trailing twelve-month EPS for Gilead Sciences, Inc. stands at -$3.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$165.83
average of 23 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy13
- Hold3
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.24 | $2.14 | -$0.95 | $10.15 |
| Low estimate | $1.05 | $2.06 | -$1.31 | $9.46 |
| High estimate | $1.42 | $2.21 | -$0.34 | $12.46 |
| No. of analysts | 13 | 4 | 16 | 16 |
| Year-ago EPS | $1.86 | $2.03 | $6.78 | — |
| Growth | -33.4% | +5.4% | -114.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $8.30B | $7.47B | $31.34B | $33.56B |
| Low estimate | $8.22B | $7.37B | $30.75B | $32.39B |
| High estimate | $8.39B | $7.58B | $31.54B | $34.17B |
| No. of analysts | 11 | 3 | 18 | 19 |
| Year-ago revenue | $7.92B | $6.96B | $29.44B | — |
| Growth | +4.7% | +7.4% | +6.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Gilead Sciences, Inc.. Gilead Sciences, Inc. has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
- AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
- GSKGSK plcDrug Manufacturers - General$101.3B
- JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
- LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
- MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
- NVSNovartis AGDrug Manufacturers - General$302.6B
- PFEPfizer Inc.Drug Manufacturers - General$164.5B
More Drug Manufacturers - General companies
- ALPMFAstellas Pharma Inc.OTC$28.1B
- ALPMYAstellas Pharma Inc.OTC$29.2B
- AMGNAmgen Inc.NASDAQ$250.1B
- AMRNAmarin Corporation plcNASDAQ$234M
- BAYRYBayer AGOTC$49.0B
- BIIBBiogen Inc.NASDAQ$37.2B
- BMYBristol-Myers Squibb CompanyNYSE$128.6B
- CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
- CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
- CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B
ETFs holding Gilead Sciences, Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.32%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.29%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets1.00%
- IVViShares Core SP 500 ETF$852.9B in assets0.33%
- BBHVanEck Biotech ETF$536M in assets14.81%
- IBBiShares Biotechnology ETF$11.1B in assets9.38%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.74%
- IYHiShares US Healthcare ETF$4.7B in assets3.08%
Largest holders first, then the funds most concentrated in GILD.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Gilead Sciences, Inc., and how their positions are changing. At a $207.86B market value, institutional positions materially move Gilead Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Gilead Sciences, Inc. executives and directors. Shares of Gilead Sciences, Inc. have traded between $87.77 and $127.68 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Gilead Sciences, Inc.. Gilead Sciences, Inc. is a $207.86B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Gilead Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Gilead Sciences, Inc.. Coverage tracks Gilead Sciences, Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Gilead Sciences, Inc.